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Abstract
Background: Autoantibodies such as anti-citrullinated protein antibodies (ACPA) are major risk factors for articular
bone destruction from the earliest phases of rheumatoid arthritis (RA). The aim of the current study was to determine
whether RA-associated autoantibodies also impact on systemic bone loss in patients with early disease.
Methods: Systemic bone mineral density (BMD) was measured in the lumbar spine and the hip in 155 consecutive
treatment-naïve patients with early RA (median symptom duration 13 weeks). Demographic and disease-specific
parameters, including clinical disease activity, ultrasonographic (US) examination of the hands and wrists, radiographic
scoring of joint damage, ACPA and rheumatoid factor (RF) levels were recorded from all patients. Reduced BMD was
defined as Z score ≤ -1 SD and analysed in relation to disease-related characteristics and autoantibody subgroups.
Results: Reduced BMD was found in 25.5 % of the patients in the spine and 19.4 % in the hip. Symptom duration,
clinical and US disease activity, functional disability and radiographic damage did not significantly impact on spine and
hip BMD loss in regression analyses adjusted for possible confounders (age, gender, menopausal status, current
smoking, body mass index). In contrast, ACPA positivity (at any level) negatively affected the spine Z-score (adjusted OR
(95 % CI) 2.76 (1.19 to 6.42)); the hip Z score was affected by high titres only (adjusted OR (95 % CI) 2.96 (1.15 to 7.66)).
The association of ACPA with reduced BMD in the spine was confirmed even at low levels of RF (adjusted OR (95 % CI)
2.65 (1.01 to 7.24)), but was further increased by concomitant high RF (adjusted OR (95 % CI) 3.38 (1.11 to 10.34)). In
contrast, Z scores in the hip were significantly reduced only in association with high ACPA and RF (adjusted OR
(95 % CI) 4.96 (1.48 to 16.64)).
Conclusions: Systemic BMD in patients with early RA is reduced in relation with ACPA positivity and high RF levels. This
finding supports the notion that RA-associated autoimmunity may have a direct causative role in bone remodeling.
Keywords: Early rheumatoid arthritis, Anti-citrullinated protein antibodies, Rheumatoid factor, Bone, Osteoporosis
* Correspondence: montecucco@smatteo.pv.it
Rheumatology and Translational Immunology Research Laboratories (LaRIT)
and Early Arthritis Clinic, Division of Rheumatology, IRCCS Policlinico San
Matteo Foundation/University of Pavia, Piazzale Golgi 19, 27100 Pavia, Italy
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bugatti et al. Arthritis Research & Therapy  (2016) 18:226 
DOI 10.1186/s13075-016-1116-9
Background
Rheumatoid arthritis (RA) is a chronic immune-
inflammatory disease associated with several forms of
skeletal remodeling including peri-articular osteope-
nia, marginal joint erosions and generalised bone loss.
Pro-inflammatory cytokines are traditionally regarded
as key drivers of articular and extra-articular bone tis-
sue destruction [1–3]. However, recent experimental
evidence indicates that RA-associated autoantibodies,
in particular anti-citrullinated protein antibodies
(ACPA), can independently stimulate bone remodeling
by inducing the differentiation of bone-resorbing oste-
oclasts [4, 5].
Clinically, the association between ACPA and fur-
ther progression in joint damage has been reported
in several independent studies, [6–8]. This associ-
ation appears at least partially independent of in-
flammation. Despite having a similar response to
steered treatment strategies, ACPA-positive patients
with RA indeed have higher rates of joint damage
progression over time [9], and serum receptor acti-
vator of nuclear factor kappa B ligand (RANKL) is
reported to be increased in ACPA-positive patients inde-
pendent of acute phase reactants and pro-inflammatory
cytokines [10]. More intriguingly, elegant imaging studies
have recently demonstrated impairment in the bone
microstructure in the metacarpophalangeal joints of
ACPA-positive healthy individuals despite no signs of
arthritis [11].
As ACPA precede the clinical onset of RA by years
and are at least initially produced at extra-articular
sites [12], it could be expected that ACPA-positive
patients with early RA may already show signs of
generalised bone loss in addition to destruction in the
joints. However, the pathophysiology of secondary
osteoporosis in RA is complex and mostly attributed
to long-standing, disabling disease [13, 14]. Accord-
ingly, the few studies available in early RA have re-
ported overall bone mineral density (BMD) almost
comparable to that of non-RA controls [15–20], and
the potential effect of autoantibodies has not been
systematically evaluated.
The Pavia Early Arthritis Clinic is a single-centre
inception cohort of patients with recent-onset in-
flammatory arthritis, who are treatment-naïve at
inclusion, and who undergo standardised clinical,
laboratory and imaging assessments upon referral
[21, 22]. Baseline BMD measurement has been
systematically introduced since 2012. Here, we took
advantage of this cohort to tackle the question of
whether RA-associated autoantibodies affect systemic
BMD independent of classical demographic and
disease-related risk factors in the initial stages of
arthritis.
Methods
Patients
Between 2012 and 2014, all patients newly referred to
the Pavia Early Arthritis Clinic with a diagnosis of RA
according to the American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
2010 classification criteria [23] were invited to undergo
dual-energy x-ray absorptiometry (DXA) at both the hip
and the spine. Patients were naïve to glucocorticoids and
disease-modifying anti-rheumatic drugs, and had arth-
ritis of short duration (<12 months of symptoms). Pa-
tients with definitive diagnoses other than RA, or any
suspicion of spondyloarthritis (including personal or
familial psoriasis and clinical or imaging evidence
enthesitis), were carefully excluded.
Demographic and general characteristics known to
affect BMD were obtained by interview and included
age, gender, ethnicity, body mass index (BMI), meno-
pausal status, age at menopause, current smoking and
alcohol status, risk factors for secondary osteoporosis
other than RA, previous clinical fractures, osteoporosis
in first-degree relatives, use of calcium and vitamin D
supplements, hormone replacement therapy and bispho-
sphonates (Table 1).
Disease variables
Disease duration was defined as the duration of patient
self-reported joint symptoms. Disease activity was
assessed using the 28-joint disease activity score
(DAS28) based on the number of tender and swollen
joints, the visual analogue scale for patient’s global as-
sessment (0–100), and the erythrocyte sedimentation
rate. C-reactive protein levels were also recorded. IgM
rheumatoid factor (RF) and ACPA were determined by
immunonephelometry using a Dimension Vista 1500
system (Siemens, Erlangen, Germany) and by a second-
generation Phadia ImmunoCAP 250 EliA CCP assay
(Phadia, Freiburg, Germany) respectively, according to
the manufacturers’ recommendations. A positive result
was defined as any value >20 IU/mL for RF and >10 IU/
mL for ACPA. A low antibody level was defined as any
value greater than the defined upper limit of normal
(ULN) and ≤100 IU/ml, and a high antibody level as a
value >100 IU/ml [24]. Different thresholds based on the
ULN [23] were not tested because of the very low num-
ber of patients with ACPA ≤3 ULN (≤30 IU/mL accord-
ing to our assay).
Functional ability was measured by the Health Assess-
ment Questionnaire Disability Index. Ultrasound (US)
examination was performed by a single experienced oper-
ator using a Logiq 9 scanner (General Electrics Medical
Systems) with a multifrequency linear array transducer
(8–15 MHz), according to EULAR guidelines [25]. The
US assessment included transverse and longitudinal
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scanning of the medial and lateral dorsal aspects of both
wrists and the first to fifth metacarpophalangeal joints, as
previously described [21, 22]. Grayscale (GS) and power
Doppler (PD) signals were assigned to each joint in ac-
cordance with semi-quantitative 0–3 scales, and an overall
US score for GS and PD was calculated as the sum of
either GS or PD signal scores obtained from each joint
(range 0–36). Radiographic joint damage according to the
Sharp–van der Heijde score (SHS) [26] was rated inde-
pendently by two experienced physicians, and the mean of
the scores of the two assessors was used for analysis.
BMD measurements
Out of 167 eligible patients, 155 agreed to undergo
BMD measurement, with no significant differences
between those who did or did not consent (not
shown). BMD measurements in the left hip (femoral
neck and total hip) and lumbar spine, vertebrae L1–4
were performed using the same DXA equipment
(Hologic, Vilvoorde, Belgium). All procedures were
performed by two trained technicians in accordance
with the manufacturer’s standardised procedures. Due
to logistic reasons, spine measurement was not per-
formed in two patients. Z score estimations were
computed through age-adjusted and gender-adjusted
BMD according to locally used reference populations
provided by the manufacturer. The Z score was used
Table 1 Demographic and clinical characteristics of the study
population
Variable Value in study
participants (n = 155)
Demographics
Age, mean (SD), years 57.8 (13.9)
Female gender, n (%) 115 (74.2)
Postmenopausal, n (%) 70 (60.9)
Age at menopause, mean (SD), years 49.7 (4.2)
Premature menopause, n (%) 3 (4.3)
Caucasian, n (%) 148 (95.5)
Body mass index, median (IQR), kg/m2 25 (22–28)
Current smoker, n (%) 30 (19.4)
Alcohol ≥3 units/day, n (%) 3 (1.9)
Comorbidities, mean number (SD) 0.4 (0.6)
Previous fracture, n (%) 7 (4.5)
Parent fractured hip, n (%) 15 (9.7)
Calcium supplementation, n (%) 2 (1.3)
Vitamin D supplementation, n (%) 3 (1.9)
Bisphosphonate use, n (%) 2 (1.3)
Hormone replacement therapy, n (%) 5 (3.2)
Disease characteristics
Symptom duration, median (IQR), weeks 12.9 (8.6–25.7)
1987 American College of Rheumatology
criteria fulfilled, n (%)
107 (69)
Disease activity score in 28 joints, mean (SD) 4.42 (1.28)
Swollen joint count in 28 joints, median (IQR) 5 (3–8)
Tender joint count in 28 joints, median (IQR) 6 (3–10)
Ultrasound grayscale score, median (IQR),
0–36 score
5 (2–9)
Ultrasound power Doppler score, median
(IQR), 0–36 score
2 (0–7)
Erythrocyte sedimentation rate, median
(IQR), mm/1 h
17 (8–33)
C-reactive protein, median (IQR), mg/dlL 0.7 (0.3–1.7)
Rheumatoid factor-positive, n (%) 67 (43.2)
Rheumatoid factor titres in positive patients,
median (IQR), U/mL
82 (34.8–195.8)
Anti-citrullinated protein antibody-positive,
n (%)
66 (42.6)
Anti-citrullinated protein antibody titres in
positive patients, median (IQR), U/mL
237 (77.5–445.8)
Erosion Sharp–van der Heijde Score ≥1,
n (%) (n = 152)
32 (21.1)
Total Sharp–van der Heijde Score, median
(IQR), 0–448 scale (n = 152)
3 (1.25–7.5)
Health Assessment Questionnaire, median
(IQR), 0–3 scale
1 (0.438–1.438)
Table 1 Demographic and clinical characteristics of the study
population (Continued)
DXA
Spine L1–L4 (n = 153)
Bone mineral density, mean (SD), g/cm2 0.936 (0.157)
Z score, mean (SD) 0.013 (1.315)
Z score ≤ -1, n (%) 39 (25.5)
- men 13 (33.3)
- premenopausal women 13 (28.9)
- postmenopausal women 13 (18.1)
Total hip (n = 155)
BMD, mean (SD), g/cm2 0.728 (0.132)
Z score, mean (SD) -0.128 (1.027)
Z score ≤ -1, n (%) 30 (19.4)
- men 7 (17.5)
- premenopausal women 12 (26.7)
- postmenopausal women 11 (15.7)
Either spine L1–L4 or total hip (n = 153)
Z score ≤1, n (%) 54 (35.3)
- men 16 (41)
- premenopausal women 19 (42.2)
- postmenopausal women 19 (27.5)
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in order to correct for the heterogeneous age and
gender of our cohort and to directly estimate the
contribution of RA-related factors beyond classical de-
terminants of primary osteoporosis [27, 28]. Reduced
BMD was defined as a Z score ≤ -1 SD [13, 14, 20].
Statistical analyses
Data were described as mean and standard deviation
(SD) or median and interquartile range (IQR) if continu-
ous and as counts and percent if categorical. Disease-
related variables in relation to the occurrence of reduced
BMD (Z score ≤ -1 SD) were analysed by regression ana-
lyses adjusted for possible confounders (age, gender,
menopausal status, current smoking and BMI). Compar-
isons between autoantibody subgroups were evaluated
using the independent samples t test or analysis of vari-
ance (ANOVA) with Bonferroni post hoc testing. Statis-
tical analyses were performed using MedCalc® Version
12.7.0.0, and the level of significance was set at 0.05.
Results
Characteristics of the study population
Table 1 shows the characteristics of the 155 patients
with early RA for whom baseline BMD was available.
The study population mainly consisted of women
(74.2 %), of whom 60.9 % were postmenopausal. Mean
(SD) age was 58 (14) years, and 76.1 % of the subjects
were <70 years of age.
Patients were treatment-naïve with a short history of
RA (median (IQR) 12.9 (8.6–25.7) weeks). Sixty-nine per-
cent also fulfilled the 1987 ACR classification criteria for
RA [29]. All had active disease (mean (SD) DAS28 4.42
(1.28)), 64.8 % had PD-positive synovitis (PD score >0),
and 21.1 % had evidence of radiographic erosions (erosion
SHS >0). Sixty-seven patients (43.2 %) were RF-positive,
66 (42.6 %) were ACPA-positive, and 58 (37.4 %) were
double-positive.
Prevalence and distribution of reduced BMD
Mean (SD) Z scores were 0.01 ± 1.31 in the spine and
-0.13 ± 1.03 in the hip. BMD was below the expected
range for gender and age (Z score ≤ -1) in the spine in
25.5 % of the patients, in the hip in 19.4 % of patients,
and in either site in 35.3 % of patients. Reduced BMD
tended to be more common in men and premenopausal
women in the spine, and in premenopausal women in
the hip (Table 1).
BMD in relation to disease duration and activity
The relationship between reduced BMD and disease var-
iables is shown in Fig. 1. Fulfillment of the 1987 ACR
criteria, symptom duration and clinical, laboratory or
imaging parameters of inflammation were not signifi-
cantly associated with Z score ≤ -1 in the measured sites.
Similarly, the very low levels of functional disability and
radiographic damage characterising our cohort did not
appear to impact on systemic BMD.
BMD in relation to autoantibody positivity and levels
ACPA-positive patients had significantly lower Z scores
in the spine compared to ACPA-negative patients (mean
-0.35 ± 1.19 vs 0.30 ± 1.34, p = 0.003), and ACPA
emerged as independent predictors of reduced BMD
with an adjusted OR (95 % CI) of 2.76 (1.19–6.42)
Fig. 1 Systemic bone mineral density in relation to disease-related variables. Regression analysis of reduced bone mineral density (Z score ≤ -1) in
the spine and the hip. Odds ratios (OR) are presented with corresponding 95 % CI levels. All variables were adjusted for age, gender, menopausal
status, body mass index and current smoking. ACR American College of Rheumatology, DAS28 28-joint disease activity score, SJC28 swollen joint
count in 28 joints, CRP C-reactive protein, US-PD ultrasonographic power Doppler score, HAQ Health Assessment Questionnaire, SHS Sharp–van
der Heijde score, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor
Bugatti et al. Arthritis Research & Therapy  (2016) 18:226 Page 4 of 8
(Fig. 1). The difference in hip Z scores was borderline
significant (mean -0.28 ± 1.03 vs 0.00 ± 1.00, p = 0.09),
whilst RF per se did not impact on either spine or hip
BMD loss (adjusted ORs (95 % CI) 2.14 (0.85 to 5.39)
and 1.58 (0.62 to 4.05) respectively) (Fig. 1).
We further questioned whether ACPA and RF levels
(rather than dichotomous positivity) had different effects
on BMD, and whether there is any interaction between
the two autoantibody systems. We thus compared Z
scores in patients with negative ACPA (<10 U), and in
those with low (10–100 U) and high (>100 U) values
[24]. On ANOVA, these subgroups differed significantly
in both the spine and the hip (Fig. 2a, b). For spine Z
scores, differences between ACPA-positive patients with
low and high values were not significant, and both sub-
groups had similarly reduced BMD compared with
ACPA-negative patients (Fig. 2a). In contrast, reductions
in Z scores in the hip were restricted to patients with
high ACPA values (Fig. 2b), and ACPA >100 U predicted
hip BMD loss with an adjusted OR (95 % CI) of 2.96
(1.15–7.66) (Fig. 1). The relationship between RF and
BMD loss was instead clearly dose-dependent in both
the spine and the hip, with significant differences being
observed for patients with high values only (Fig. 2c, d).
When combining ACPA with RF titres, it was evi-
dent that the presence of ACPA negatively affected
the Z score in the spine even in the presence of low
levels of RF (difference in means (Δmeans) 0.50, SE
0.26 compared to seronegative patients), but RF >100
U conferred additional risk (Δmeans 0.50, SE 0.30
compared to patients who were ACPA-positive RF-low)
(Fig. 2e). Accordingly, the adjusted OR (95 % CI) of ACPA
in predicting spine Z score ≤ -1 increased from 2.65
(1.01–7.24) in the presence of concomitant RF ≤100 to
3.38 (1.11–10.34) for RF >100. In contrast, Z scores in the
hip were significantly reduced only in association with
high ACPA and RF. (Fig. 2f). ACPA >100 and RF >100
predicted reduced BMD in the hip with an adjusted OR
(95 %) of 4.96 (1.48–16.64).
Discussion
We show here that, overall, systemic BMD is preserved
in patients with early RA, and classic disease-related risk
factors, including disease duration, inflammatory activity
Fig. 2 Association between systemic bone mineral density and anti-citrullinated protein antibodies and/or rheumatoid factor. Mean Z scores in
the lumbar spine, vertebrae L1-L4 (a, c, e) and total hip (b, d, f) in subgroups of patients stratified according to anti-citrullinated protein antibody
(ACPA) titres (a, b), rheumatoid factor (RF) titres (c, d) and the combination of ACPA and RF (e, f). *Significant differences (p <0.05)
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and functional ability, have negligible impact on measur-
able bone remodeling at this stage of the disease. How-
ever, ACPA appear associated with significantly reduced
BMD, and the concomitant presence of high levels of RF
further enhances the risk of bone loss. Whilst the effect
of ACPA on the trabecular bone of the spine is readily
appreciable, changes in the cortical bone of the hip
require higher levels of autoantibodies.
The small proportion of patients with reduced BMD
in our study is consistent with earlier reports [15–20]
and confirms that overt secondary osteoporosis in RA
mostly develops in association with chronic, disabling
disease. The short symptom duration and the low levels
of functional impairment and radiographic damage in
our contemporary cohort diagnosed according to the
2010 criteria may explain the lack of association between
disease-related factors and BMD, as compared with
historical groups of patients with early RA with longer
disease duration and variable treatment [15, 19, 20].
Whilst synovial inflammation may thus take longer to
produce systemic effects at joint-remote sites [30], we
show here that RA-associated autoimmunity appears
coupled with reduced BMD from the early stages of
clinical disease. Although functional verification of the
pathogenic effects of autoantibodies on extra-articular
bone in our study is lacking, our data fit with recent evi-
dence linking ACPA to bone changes in vitro and in vivo
[4–6]. Relevantly, the association between ACPA and
BMD loss was enhanced by high levels of RF. Sensitive
imaging techniques have shown that RF dose-dependently
influences the size of bone erosions on an ACPA back-
ground [24], and the combined presence of ACPA and RF
mediates increased pro-inflammatory cytokine production
in vitro [31, 32]. The immune-complex activity of RF may
have thus elicited a subclinical inflammatory milieu
able to enhance ACPA-mediated osteoclast activation
also at joint-remote sites. The different associations
between autoantibody levels and spine and hip BMD
loss might be explained by the higher rate of turnover
in trabecular compared to cortical bone [33].
Our study has some limitations. Although we cannot
exclude RA over-diagnosis according to the 2010 criteria
[34], differential diagnoses were carefully evaluated and
applying the 1987 criteria did not affect the results. The
frequency of autoantibodies was lower than expected
[35–37], but still comparable with other early arthritis
cohorts from similar geographical areas [38], including
the Etude et Suivi des POlyarthrites Indifférenciées
Récentes (ESPOIR) cohort, in which 46–49 % of the
patients fulfilling the RA classification criteria at inclu-
sion are reported as ACPA-positive [39–41]. Irrespective
of the prevalence of autoantibodies, however, we believe
that the observed differences in BMD according to
autoantibody levels clearly confirm the specific association
between RA autoimmunity and systemic bone loss.
Although the small number of single-positive patients
hampers definitive conclusions on the independent associ-
ations with ACPA and RF, spine BMD was significantly
reduced in ACPA-positive patients with low RF (Fig. 1e)
in the absence of the definitive effects of low RF (Fig. 1c).
This finding indirectly supports the notion that ACPA are
key drivers of bone damage, and RF becomes important
when ACPA are also present [24]. Also, the cross-
sectional character of this study hampers definition of the
potential effect of autoantibodies on the progression of
BMD loss. DXA follow up is ongoing to define whether
treatment can halt autoantibody-dependent systemic bone
remodeling. It is also equally important to emphasise that
additional measures of bone quality, including micro-
architecture, mineralisation and turnover [42–44], might
help better define the net impact of autoantibodies and
autoantibody levels on bone. Finally, it is important to recall
that vitamin-D is a key determinant of bone health [45], and
patients with RA have significantly lower vitamin D serum
levels compared to healthy controls [46]. As vitamin D
deficiency might be more prevalent in ACPA-positive patients
[47], we cannot exclude that possibility that the observed
association between autoantibodies and reduced BMD might
be at least partly mediated by lower vitamin D levels.
Conclusions
In summary, our data suggest that ACPA are associated
with systemic bone loss from the earliest stages of RA,
and high levels of RF further increase the risk. ACPA-RF-
positive patients with early RA should thus be carefully
monitored for the development of generalised osteopor-
osis beyond the assessment of traditional risk factors.
Abbreviations
ACPA: Anti-citrullinated protein antibodies; ACR: American College of
Rheumatology; ANOVA: Analysis of variance; BMD: Bone mineral density;
BMI: Body mass index; CI: Confidence interval; DAS28: 28-joint disease activity
score; DXA: Dual-energy x-ray absorptiometry; EULAR: European League
Against Rheumatism; GS: Grayscale; IQR: Interquartile range; OR: Odds ratio;
PD: Power Doppler; RA: Rheumatoid arthritis; RF: Rheumatoid factor;
SD: Standard deviation; SHS: Sharp–van der Heijde score; ULN: Upper limit of
normal; US: Ultrasonography
Funding
This study was supported in part by funding from the IRCCS Policlinico San
Matteo Foundation, Pavia, Italy.
Availability of data and materials
The datasets analysed in the current study are available from the
corresponding author on reasonable request.
Authors’ contributions
SB designed the study, collected and analysed the data and drafted the
manuscript. LB collected the data and helped to revise the manuscript. AM
participated in the design of the study and helped to draft the manuscript.
BV performed laboratory assays and helped to revise the manuscript. CM
designed the study and critically revised the manuscript. RC critically revised
the manuscript and provided final approval. All authors read and approved
the final manuscript.
Bugatti et al. Arthritis Research & Therapy  (2016) 18:226 Page 6 of 8
Competing interests
The authors declare that they have no competing interests with regard to
this study.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The current study was approved by the local Ethics Committee of the IRCCS
Policlinico San Matteo Foundation, Pavia, Italy, and written informed consent
was obtained from all patients.
Received: 12 July 2016 Accepted: 13 September 2016
References
1. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question
of balance. Immunol Rev. 2010;233:301–12.
2. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms,
diagnosis and treatment. Nat Rev Rheumatol. 2012;8:656–64.
3. Bugatti S, Manzo A, Caporali R, Montecucco C. Assessment of synovitis to
predict bone erosions in rheumatoid arthritis. Ther Adv Musculoskelet Dis.
2012;4:235–44.
4. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al.
Induction of osteoclastogenesis and bone loss by human autoantibodies
against citrullinated vimentin. J Clin Invest. 2012;122:1791–802.
5. Krishnamurthy A, Joshua V, Haj Hensvold A, Jin T, Sun M, Vivar N, et al.
Identification of a novel chemokine-dependent molecular mechanism
underlying rheumatoid arthritis-associated autoantibody-mediated bone
loss. Ann Rheum Dis. 2016;75:721–9.
6. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al.
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP)
during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts
worse disease activity and greater radiological progression. Ann Rheum Dis.
2005;64:1744–9.
7. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW.
Antibodies to citrullinated proteins and differences in clinical progression of
rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949–58.
8. Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P,
et al. High anti-cyclic citrullinated peptide levels and an algorithm of four
variables predict radiographic progression in patients with rheumatoid arthritis:
results from a 10-year longitudinal study. Ann Rheum Dis. 2008;67:212–7.
9. van den Broek M, Dirven L, Klarenbeek NB, Molenaar TH, Han KH, Kerstens
PJ, et al. The association of treatment response and joint damage with
ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the
BeSt study. Ann Rheum Dis. 2012;71:245–8.
10. Hensvold AH, Joshua V, Li W, Larkin M, Qureshi F, Israelsson L, et al.
Serum RANKL levels associate with anti- citrullinated protein antibodies in
early untreated rheumatoid arthritis and are modulated following
methotrexate. Arthritis Res Ther. 2015;17:239.
11. Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, et al. Bone loss
before the clinical onset of rheumatoid arthritis in subjects with
anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73:854–60.
12. Catrina AI, Joshua V, Klareskog L, Malmström V. Mechanisms involved in
triggering rheumatoid arthritis. Immunol Rev. 2016;269:162–74.
13. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density
and frequency of osteoporosis in female patients with rheumatoid arthritis:
results from 394 patients in the Oslo County Rheumatoid Arthritis register.
Arthritis Rheum. 2000;43:522–30.
14. Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE, et al.
Bone mineral density in patients with rheumatoid arthritis: relation
between disease severity and low bone mineral density. Ann Rheum Dis.
2004;63:1576–80.
15. Laan RF, Buijs WC, Verbeek AL, Draad MP, Corstens FH, van de Putte LB,
et al. Bone mineral density in patients with recent onset rheumatoid
arthritis: influence of disease activity and functional capacity. Ann Rheum
Dis. 1993;52:21–6.
16. Shenstone BD, Mahmoud A, Woodward R, Elvins D, Palmer R, Ring F, et al.
Bone mineral density in nonsteroid treated early rheumatoid arthritis.
Ann Rheum Dis. 1994;53:681–4.
17. Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in
patients with early rheumatoid arthritis. Lancet. 1994;344:23–7.
18. Keller C, Hafström I, Svensson B. Bone mineral density in women and men
with early rheumatoid arthritis. Scand J Rheumatol. 2001;30:213–20.
19. Forslind K, Keller C, Svensson B, Hafström I, BARFOT Study Group.
Reduced bone mineral density in early rheumatoid arthritis is
associated with radiological joint damage at baseline and after
2 years in women. J Rheumatol. 2003;30:2590–6.
20. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK,
Ronday HK, Peeters AJ, et al. Bone mineral density in patients with recently
diagnosed, active rheumatoid arthritis. Ann Rheum Dis. 2007;66:1508–12.
21. Montecucco C, Todoerti M, Sakellariou G, Sciré CA, Caporali R. Low-dose
oral prednisone improves clinical and ultrasonographic remission rates in
early rheumatoid arthritis: results of a 12-month open-label randomised
study. Arthritis Res Ther. 2012;14:R112.
22. Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, et al.
Serum levels of CXCL13 are associated with ultrasonographic synovitis and
predict power Doppler persistence in early rheumatoid arthritis treated with
non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther.
2012;14:R34.
23. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al.
2010 rheumatoid arthritis classification criteria: an American College of
Rheumatology/European League Against Rheumatism collaborative
initiative. Ann Rheum Dis. 2010;69:1580–8.
24. Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, et al.
Additive effect of anti-citrullinated protein antibodies and rheumatoid factor
on bone erosions in patients with RA. Ann Rheum Dis. 2015;74:2151–6.
25. Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, et al.
Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis.
2001;60:641–9.
26. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW. vad de Putte LB.
Effects of hydroxychloroquine and sulphasalazine on progression of joint
damage in rheumatoid arthritis. Lancet. 1989;1:1036–8.
27. Leslie WD, Adler RA, El-Hajj Fuleihan G, Hodsman AB, Kendler DL, McClung M,
et al. Application of the 1994 WHO classification to populations other than
postmenopausal Caucasian women: the 2005 ISCD Official Positions.
J Clin Densitom. 2006;9:22–30.
28. Rossini M, Viapiana O, Idolazzi L, Ghellere F, Fracassi E, Troplini S, et al.
Higher level of Dickkopf-1 is associated with low bone mineral density and
higher prevalence of vertebral fractures in patients with ankylosing
spondylitis. Calcif Tissue Int. 2016;98:438–45.
29. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
30. Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK,
van Groenendael JH, Mallée C, et al. Changes in hand and generalised
bone mineral density in patients with recent-onset rheumatoid arthritis.
Ann Rheum Dis. 2009;68:330–6.
31. Sokolove J, Johnson DS, Lahey LJ, Wagner CA, Cheng D, Thiele GM, et al.
Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-
mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol.
2014;66:813–21.
32. Laurent L, Anquetil F, Clavel C, Ndongo-Thiam N, Offer G, Miossec P, et al.
IgM rheumatoid factor amplifies the inflammatory response of
macrophages induced by the rheumatoid arthritis-specific immune
complexes containing anticitrullinated protein antibodies. Ann Rheum Dis.
2015;74:1425–31.
33. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, et al.
Receptor activator of nuclear factor kB ligand (RANKL) protein expression by
B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem.
2012;287:29851–60.
34. van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH.
Classification of rheumatoid arthritis: comparison of the 1987 American
College of Rheumatology criteria and the 2010 American College of
Rheumatology/European League Against Rheumatism criteria.
Arthritis Rheum. 2011;63:37–42.
35. Norli ES, Brinkmann GH, Kvien TK, Bjørneboe O, Haugen AJ, Nygaard H,
et al. Self-limiting arthritis among patients fulfilling the 2010 ACR/EULAR
classification criteria for rheumatoid arthritis in a very early arthritis
cohort. Semin Arthritis Rheum. 2016;16:30119–6. doi:10.1016/j.semarthrit.
2016.07.004.
Bugatti et al. Arthritis Research & Therapy  (2016) 18:226 Page 7 of 8
36. Nieuwenhuis WP, de Wit MP, Boonen A, van der Helm-van Mil AH. Changes
in the clinical presentation of patients with rheumatoid arthritis from the
early 1990s to the years 2010: earlier identification but more severe
patient reported outcomes. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-
2016-209949.
37. Cader MZ, Filer A, Hazlehurst J, de Pablo P, Buckley CD, Raza K. Performance of
the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987
ACR criteria in a very early synovitis cohort. Ann Rheum Dis. 2011;70:949–55.
38. Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R,
et al. Very early rheumatoid arthritis as a predictor of remission: a
multicentre real life prospective study. Ann Rheum Dis. 2013;72:858–62.
39. Durán J, Combe B, Niu J, Rincheval N, Gaujoux-Viala C, Felson DT. The effect on
treatment response of fibromyalgic symptoms in early rheumatoid arthritis
patients: results from the ESPOIR cohort. Rheumatology. 2015;54:2166–70.
40. Ruyssen-Witrand A, van Steenbergen HW, van Heemst J, Gourraud PA,
Nigon D, Lukas C, et al. A new classification of HLA-DRB1 alleles based on
acid-base properties of the amino acids located at positions 13, 70 and 71:
impact on ACPA status or structural progression, and meta-analysis on 1235
patients with rheumatoid from two cohorts (ESPOIR and EAC cohort).
RMD Open. 2015;1, e000099.
41. Fautrel B, Combe B, Rincheval N, Dougados M. ESPOIR Scientific Committee.
Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid
arthritis classification criteria: an analysis based on ESPOIR cohort data.
Ann Rheum Dis. 2012;71:386–9.
42. Mawatari T, Miura H, Hamai S, Shuto T, Nakashima Y, Okazaki K, et al.
Vertebral strength changes in rheumatoid arthritis patients treated with
alendronate, as assessed by finite element analysis of clinical computed
tomography scans: a prospective randomized clinical trial. Arthritis Rheum.
2008;58:3340–9.
43. Koumakis E, Avouac J, Winzenrieth R, Toth E, Payet J, Kahan A, et al.
Trabecular bone score in female patients with systemic sclerosis:
comparison with rheumatoid arthritis and influence of glucocorticoid
exposure. J Rheumatol. 2015;42:228–35.
44. Coiffier G, Bouvard B, Chopin F, Biver E, Funck-Brentano T, Garnero P, et al.
Common bone turnover markers in rheumatoid arthritis and ankylosing
spondylitis: a literature review. Joint Bone Spine. 2013;80:250–7.
45. Carmeliet G, Dermauw V, Bouillon R. Vitamin D signaling in calcium and
bone homeostasis: a delicate balance. Best Pract Res Clin Endocrinol Metab.
2015;29:621–31.
46. Lin J, Liu J, Davies ML, Chen W. Serum vitamin D level and rheumatoid
arthritis disease activity: review and meta-analysis. PLoS One. 2016;11,
e0146351.
47. Kerr GS, Sabahi I, Richards JS, Caplan L, Cannon GW, Reimold A, et al.
Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and
associations with disease severity and activity. J Rheumatol. 2011;38:53–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bugatti et al. Arthritis Research & Therapy  (2016) 18:226 Page 8 of 8
